TN2013000324A1 - 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors - Google Patents
6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitorsInfo
- Publication number
- TN2013000324A1 TN2013000324A1 TNP2013000324A TN2013000324A TN2013000324A1 TN 2013000324 A1 TN2013000324 A1 TN 2013000324A1 TN P2013000324 A TNP2013000324 A TN P2013000324A TN 2013000324 A TN2013000324 A TN 2013000324A TN 2013000324 A1 TN2013000324 A1 TN 2013000324A1
- Authority
- TN
- Tunisia
- Prior art keywords
- medicaments
- pyrazolo
- pyrimidin
- cyclobutyl
- dihydro
- Prior art date
Links
- ZPVYNDTUAWQPAP-UHFFFAOYSA-N 6-cyclobutyl-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical class C1(CCC1)C=1NC(C2=C(N1)NN=C2)=O ZPVYNDTUAWQPAP-UHFFFAOYSA-N 0.000 title 1
- 229940122229 Phosphodiesterase 9A inhibitor Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000028252 learning or memory Effects 0.000 abstract 1
- 230000008447 perception Effects 0.000 abstract 1
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11154397 | 2011-02-14 | ||
| PCT/EP2011/063705 WO2012020022A1 (fr) | 2010-08-12 | 2011-08-09 | Dérivés de 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leurs utilisations en tant qu'inhibiteurs de pde9a |
| PCT/EP2012/052378 WO2012110440A1 (fr) | 2011-02-14 | 2012-02-13 | Dérivés de 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one et leur utilisation en tant qu'inhibiteurs de pde9a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000324A1 true TN2013000324A1 (en) | 2015-01-20 |
Family
ID=46671960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000324A TN2013000324A1 (en) | 2011-02-14 | 2013-07-29 | 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130040971A1 (fr) |
| EP (1) | EP2675807B1 (fr) |
| JP (1) | JP2014505091A (fr) |
| KR (1) | KR20140010036A (fr) |
| CN (1) | CN103459397A (fr) |
| AP (1) | AP2013007045A0 (fr) |
| AR (1) | AR085219A1 (fr) |
| AU (1) | AU2012217208A1 (fr) |
| BR (1) | BR112013020605A2 (fr) |
| CA (1) | CA2827261A1 (fr) |
| CL (1) | CL2013002341A1 (fr) |
| CO (1) | CO6791616A2 (fr) |
| EA (1) | EA023574B1 (fr) |
| EC (1) | ECSP13012852A (fr) |
| IL (1) | IL227526A0 (fr) |
| MA (1) | MA34889B1 (fr) |
| MX (1) | MX2013009343A (fr) |
| PE (1) | PE20140970A1 (fr) |
| PH (1) | PH12013501677A1 (fr) |
| SG (1) | SG192756A1 (fr) |
| TN (1) | TN2013000324A1 (fr) |
| TW (1) | TW201245199A (fr) |
| WO (1) | WO2012110440A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| EP2151435A4 (fr) | 2007-04-24 | 2011-09-14 | Shionogi & Co | Composition pharmaceutique pour le traitement de la maladie d'alzheimer |
| EP2689780A1 (fr) | 2007-04-24 | 2014-01-29 | Shionogi & Co., Ltd. | Intermédiaires de dérivés d'aminodihydrothiazine substitués avec un groupe cyclique |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| EP2305672B1 (fr) | 2008-06-13 | 2019-03-27 | Shionogi & Co., Ltd. | DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITÉ INHIBANT LA ß-SÉCRÉTASE |
| EP2360155A4 (fr) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-aminopyridin-4-one et dérivé de 2-aminopyridine dont l'activité inhibe la bace1 |
| CA2757231A1 (fr) * | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | Derives 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a |
| CN102834384A (zh) | 2009-12-11 | 2012-12-19 | 盐野义制药株式会社 | *嗪衍生物 |
| WO2012057247A1 (fr) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | Dérivé d'aminodihydropyrimidine fusionnée |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| EP2912035A4 (fr) | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| WO2018221546A1 (fr) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Composition pharmaceutique comprenant un inhibiteur de pde9 |
| WO2018221551A1 (fr) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy |
| MX392609B (es) | 2017-06-01 | 2025-03-19 | Eisai R&D Man Co Ltd | Agente terapéutico para la demencia que combina derivado de pirazoloquinolina y memantina. |
| EP3632439B1 (fr) | 2017-06-01 | 2024-03-27 | Eisai R&D Management Co., Ltd. | Agent thérapeutique pour la démence combinant un dérivé de pyrazoloquinoline et du donépézil |
| TW201902898A (zh) * | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
| EP3893881B1 (fr) * | 2018-12-12 | 2024-10-09 | Merck Sharp & Dohme LLC | Inhibiteurs de pde9 au pyrazolopyrimidine cyclobutyle |
| CN110339197A (zh) * | 2019-06-24 | 2019-10-18 | 中山大学 | 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH396924A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen |
| CH396926A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
| CH396927A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
| DE1147234B (de) | 1960-05-11 | 1963-04-18 | Ciba Geigy | Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-6-benzyl-pyrazolo[3, 4-d]pyrimidin |
| CH396925A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
| DE1149013B (de) | 1960-05-11 | 1963-05-22 | Ciba Geigy | Verfahren zur Herstellung von 4-Oxo-4, 5-dihydro-pyrazolo-[3, 4-d]Pyrimidinen |
| US3732225A (en) | 1970-07-23 | 1973-05-08 | Squibb & Sons Inc | Pyrazolo(3,4-d)pyrimidine derivatives |
| US3847908A (en) | 1973-03-05 | 1974-11-12 | Squibb & Sons Inc | 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines |
| ES2203635T3 (es) | 1994-04-27 | 2004-04-16 | Novartis Ag | Nucleosidos y oligonucleotidos con grupos 2'-eter. |
| CZ126799A3 (cs) | 1996-10-16 | 1999-07-14 | Icn Pharmaceuticals | Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| EP1296690A2 (fr) | 2000-02-18 | 2003-04-02 | Shire Biochem Inc. | METHODE DE TRAITEMENT OU DE PREVENTION D'INFECTIONS A i FLAVIVIRUS /i A L'AIDE D'ANALOGUES NUCLEOSIDIQUES |
| WO2002019213A2 (fr) * | 2000-08-30 | 2002-03-07 | Lilly Icos Llc | Procede de traitement de la migraine |
| EP1539188B1 (fr) | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale arn-dependante |
| AU2003252003A1 (en) | 2002-07-19 | 2004-02-09 | David B. Mossor | Portable shielding system |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| US8044060B2 (en) * | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
| JP2006525966A (ja) * | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類 |
| US7351827B2 (en) | 2003-11-21 | 2008-04-01 | The University Of Connecticut | Substituted oxetanes, method of making, and method of use thereof |
| US7951810B2 (en) | 2005-02-04 | 2011-05-31 | Millennium Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes |
| GEP20125405B (en) * | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
| PE20091211A1 (es) | 2007-11-30 | 2009-09-14 | Boehringer Ingelheim Int | Derivados de pirazolopirimidina como moduladores de pde9a |
| UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| EP2334684B1 (fr) * | 2008-09-08 | 2017-08-02 | Boehringer Ingelheim International GmbH | Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc |
| CA2757231A1 (fr) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | Derives 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a |
| AR077859A1 (es) * | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
| KR101918909B1 (ko) * | 2010-08-12 | 2018-11-15 | 베링거 인겔하임 인터내셔날 게엠베하 | ６사이클로알킬１，５디하이드로피라졸로［３，４ｄ］피리미딘４온 유도체 및 이의 ｐｄｅ９ａ 억제제로서의 용도 |
-
2012
- 2012-02-09 US US13/369,623 patent/US20130040971A1/en not_active Abandoned
- 2012-02-13 TW TW101104596A patent/TW201245199A/zh unknown
- 2012-02-13 PH PH1/2013/501677A patent/PH12013501677A1/en unknown
- 2012-02-13 EP EP20120705246 patent/EP2675807B1/fr active Active
- 2012-02-13 CN CN2012800177072A patent/CN103459397A/zh active Pending
- 2012-02-13 AP AP2013007045A patent/AP2013007045A0/xx unknown
- 2012-02-13 CA CA2827261A patent/CA2827261A1/fr not_active Abandoned
- 2012-02-13 MX MX2013009343A patent/MX2013009343A/es active IP Right Grant
- 2012-02-13 WO PCT/EP2012/052378 patent/WO2012110440A1/fr not_active Ceased
- 2012-02-13 MA MA36160A patent/MA34889B1/fr unknown
- 2012-02-13 AR ARP120100472A patent/AR085219A1/es unknown
- 2012-02-13 BR BR112013020605A patent/BR112013020605A2/pt not_active IP Right Cessation
- 2012-02-13 AU AU2012217208A patent/AU2012217208A1/en not_active Abandoned
- 2012-02-13 JP JP2013552980A patent/JP2014505091A/ja active Pending
- 2012-02-13 EA EA201300908A patent/EA023574B1/ru not_active IP Right Cessation
- 2012-02-13 PE PE2013001871A patent/PE20140970A1/es not_active Application Discontinuation
- 2012-02-13 KR KR1020137021400A patent/KR20140010036A/ko not_active Withdrawn
- 2012-02-13 SG SG2013061494A patent/SG192756A1/en unknown
-
2013
- 2013-07-18 IL IL227526A patent/IL227526A0/en unknown
- 2013-07-29 TN TNP2013000324A patent/TN2013000324A1/fr unknown
- 2013-08-12 CL CL2013002341A patent/CL2013002341A1/es unknown
- 2013-08-26 EC ECSP13012852 patent/ECSP13012852A/es unknown
- 2013-09-12 CO CO13216891A patent/CO6791616A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA023574B1 (ru) | 2016-06-30 |
| SG192756A1 (en) | 2013-09-30 |
| EP2675807A1 (fr) | 2013-12-25 |
| TW201245199A (en) | 2012-11-16 |
| ECSP13012852A (es) | 2014-09-30 |
| AU2012217208A1 (en) | 2013-08-01 |
| US20130040971A1 (en) | 2013-02-14 |
| MX2013009343A (es) | 2013-10-01 |
| CL2013002341A1 (es) | 2014-04-04 |
| AR085219A1 (es) | 2013-09-18 |
| WO2012110440A1 (fr) | 2012-08-23 |
| JP2014505091A (ja) | 2014-02-27 |
| PE20140970A1 (es) | 2014-08-03 |
| EP2675807B1 (fr) | 2015-04-22 |
| KR20140010036A (ko) | 2014-01-23 |
| CA2827261A1 (fr) | 2012-08-23 |
| EA201300908A1 (ru) | 2014-01-30 |
| WO2012110440A9 (fr) | 2013-03-14 |
| BR112013020605A2 (pt) | 2016-10-18 |
| AP2013007045A0 (en) | 2013-08-31 |
| PH12013501677A1 (en) | 2018-04-11 |
| IL227526A0 (en) | 2013-09-30 |
| CN103459397A (zh) | 2013-12-18 |
| CO6791616A2 (es) | 2013-11-14 |
| MA34889B1 (fr) | 2014-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000324A1 (en) | 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors | |
| MY170189A (en) | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors | |
| TN2011000493A1 (en) | 1-heterocyclyl -1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin -4- one derivatives and their use as pde9a modulators | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| IN2014DN07384A (fr) | ||
| JO3397B1 (ar) | بيريدينكاربوكسيميدات [1, 2-a] إيميدازول مستبدل مع أمينو واستخداماتها | |
| PH12013500872A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| WO2012170976A3 (fr) | Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk | |
| EA201201191A1 (ru) | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
| WO2014033447A3 (fr) | Inhibiteurs de kinase | |
| MX2010007523A (es) | Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer. | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| NZ629499A (en) | Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases | |
| NZ630580A (en) | 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer | |
| BR112015000459A2 (pt) | inibidores da enzima fosfodiesterase 10 | |
| TN2016000121A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
| MY164134A (en) | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring | |
| UA106368C2 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
| TN2013000146A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| WO2010015586A3 (fr) | Composés 2,3,4,7-tétrahydro-indolo[2,3-c]quinoléine | |
| ECSP13012483A (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d) pirimidin-4-onas y su uso como inhibidores de pde9a. |